The Latest Cardiac and Vascular News
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke AUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin […]
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke AUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) — XBiotech (NASDAQ: XBIT) announced today its plan to commence a randomized, placebo-controlled clinical study to test its new True Human™ antibody therapy […]
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders […]
AUSTIN, Texas, August 27, 2018 (GLOBE NEWSWIRE) – XBiotech Inc. (NASDAQ: XBIT) today announced the release of results indicating that leukocyte-derived Interleukin-1 alpha (IL-1⍺) is the cause clots that can cause a heart attack or stroke. The research was led by a world-renowned cardiovascular researcher, Dr. Peter Libby, Professor Mallinckrodt of […]
